Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237430 | 0.91 | PSEN1 (0.52) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1783083 | 0.79 | EEF2K (0.50) | EEF2KMAPTPSEN1PSEN2APH1B | |
| SCHEMBL8241071 | 0.76 | PSEN1 (0.42) | EEF2KPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18211725 | 0.76 | MAP3K14 (0.50) | MAP3K14APP | |
| SCHEMBL8237395 | 0.75 | PSEN1 (0.45) | EEF2KPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8237678 | 0.72 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8231815 | 0.70 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5399703 | 0.66 | MAP3K14 (0.49) | MAP3K14APP | |
| SCHEMBL6605548 | 0.66 | MAP3K14 (0.49) | MAP3K14APP | |
| SCHEMBL6605552 | 0.66 | MAP3K14 (0.49) | MAP3K14APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-1976843-B1 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | BACE1, PSEN1, BACE2 | EEF2K 2961/4885PKM 4045/4885PKLR 3589/4885 |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | BACE1, BACE2, PSEN1 | EEF2K 3122/4885PKM 4020/4885PKLR 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.